Trial Outcomes & Findings for A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder (NCT NCT02288325)

NCT ID: NCT02288325

Last Updated: 2018-10-29

Results Overview

Time to relapse for the median was measured in days from randomization date at the start of the DBTP to relapse date during DBTP. Relapse was defined as meeting any 1 or more of the following criteria: 1) Insufficient therapeutic response at any one visit, including a \>/= 2 increase in Clinical Global Impressions-Severity (CGI-S) score (range 1 to 7) compared with that obtained at randomization, or risk of suicide as determined by the investigator, or need for hospitalization due to worsening of depression as determined by the investigator, or need for alternative treatment of depressive symptoms as determined by the Investigator; 2) Montgomery-Asberg Depression Rating Scale (MADRS) total score \>/= 18 (range 0 to 60) at 2 consecutive visits (second visit within 7 to 14 days after the first visit at which the MADRS total score was ≥ 18). Participant was considered censored at the last visit during DBTP if participant did not meet the relapse criteria during DBTP.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

644 participants

Primary outcome timeframe

From the randomization date (Week 20) to the relapse date during the 26-week DBTP (up to Week 46)

Results posted on

2018-10-29

Participant Flow

Participant milestones

Participant milestones
Measure
Open-Label FETZIMA®
FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
Double-Blind Placebo
Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
Double-Blind FETZIMA®
FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
Run-in Period
STARTED
644
0
0
Run-in Period
COMPLETED
499
0
0
Run-in Period
NOT COMPLETED
145
0
0
Stabilization Period
STARTED
429
0
0
Stabilization Period
COMPLETED
331
0
0
Stabilization Period
NOT COMPLETED
98
0
0
Double-blind Treatment Period
STARTED
0
159
165
Double-blind Treatment Period
COMPLETED
0
135
139
Double-blind Treatment Period
NOT COMPLETED
0
24
26

Reasons for withdrawal

Reasons for withdrawal
Measure
Open-Label FETZIMA®
FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
Double-Blind Placebo
Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
Double-Blind FETZIMA®
FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
Run-in Period
Adverse Event
48
0
0
Run-in Period
Lack of Efficacy
16
0
0
Run-in Period
Withdrawal of Consent
28
0
0
Run-in Period
Lost to Follow-up
25
0
0
Run-in Period
Protocol Violation
17
0
0
Run-in Period
Non-Compliance With Study Drug
3
0
0
Run-in Period
Reason not Specified
8
0
0
Stabilization Period
Adverse Event
13
0
0
Stabilization Period
Lack of Efficacy
22
0
0
Stabilization Period
Withdrawal of Consent
23
0
0
Stabilization Period
Lost to Follow-up
12
0
0
Stabilization Period
Protocol Violation
8
0
0
Stabilization Period
Non-Compliance With Study Drug
5
0
0
Stabilization Period
Reason not Specified
15
0
0
Double-blind Treatment Period
Adverse Event
0
2
5
Double-blind Treatment Period
Withdrawal of Consent
0
8
8
Double-blind Treatment Period
Lost to Follow-up
0
4
5
Double-blind Treatment Period
Protocol Violation
0
1
2
Double-blind Treatment Period
Non-Compliance With Study Drug
0
1
4
Double-blind Treatment Period
Multiple Reasons
0
8
2

Baseline Characteristics

A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive Disorder

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Open-Label FETZIMA®
n=644 Participants
FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
Age, Continuous
43.1 years
STANDARD_DEVIATION 13.9 • n=5 Participants
Sex: Female, Male
Female
404 Participants
n=5 Participants
Sex: Female, Male
Male
240 Participants
n=5 Participants

PRIMARY outcome

Timeframe: From the randomization date (Week 20) to the relapse date during the 26-week DBTP (up to Week 46)

Population: Double-blind Intent-to-Treat (ITT) population comprised of all participants in the Double-blind Safety Population who had at least 1 post-randomization assessment of MADRS or those participants who met relapse criteria during the DBTP of the study.

Time to relapse for the median was measured in days from randomization date at the start of the DBTP to relapse date during DBTP. Relapse was defined as meeting any 1 or more of the following criteria: 1) Insufficient therapeutic response at any one visit, including a \>/= 2 increase in Clinical Global Impressions-Severity (CGI-S) score (range 1 to 7) compared with that obtained at randomization, or risk of suicide as determined by the investigator, or need for hospitalization due to worsening of depression as determined by the investigator, or need for alternative treatment of depressive symptoms as determined by the Investigator; 2) Montgomery-Asberg Depression Rating Scale (MADRS) total score \>/= 18 (range 0 to 60) at 2 consecutive visits (second visit within 7 to 14 days after the first visit at which the MADRS total score was ≥ 18). Participant was considered censored at the last visit during DBTP if participant did not meet the relapse criteria during DBTP.

Outcome measures

Outcome measures
Measure
Double-Blind Placebo
n=159 Participants
Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
Double-Blind FETZIMA®
n=165 Participants
FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
Time to First Relapse During the Double-Blind Treatment Period (DBTP)
NA days
Not available due to insufficient number of events.
NA days
Not available due to insufficient number of events.

Adverse Events

Open-Label FETZIMA®

Serious events: 9 serious events
Other events: 430 other events
Deaths: 0 deaths

Double-Blind Placebo

Serious events: 1 serious events
Other events: 29 other events
Deaths: 0 deaths

Double-Blind FETZIMA®

Serious events: 2 serious events
Other events: 41 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Open-Label FETZIMA®
n=644 participants at risk
FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
Double-Blind Placebo
n=159 participants at risk
Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
Double-Blind FETZIMA®
n=165 participants at risk
FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
Psychiatric disorders
Panic attack
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Oesophageal squamous cell carcinoma
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Nervous system disorders
Migraine
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Psychiatric disorders
Mania
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Infections and infestations
Influenza
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Metabolism and nutrition disorders
Hyponatraemia
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Gastrointestinal disorders
Gastrointestinal haemorrhage
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Hepatobiliary disorders
Cholecystitis acute
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Hepatobiliary disorders
Bile duct stone
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Psychiatric disorders
Agitation
0.16%
1/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Nervous system disorders
Transient ischaemic attack
0.00%
0/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.61%
1/165 • Up to 48 weeks
Infections and infestations
Escherichia pyelonephritis
0.00%
0/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.61%
1/165 • Up to 48 weeks
Injury, poisoning and procedural complications
Overdose
0.00%
0/644 • Up to 48 weeks
0.63%
1/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Investigations
Intraocular pressure increased
0.00%
0/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Infections and infestations
Pelvic inflammatory disease
0.00%
0/644 • Up to 48 weeks
0.00%
0/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks

Other adverse events

Other adverse events
Measure
Open-Label FETZIMA®
n=644 participants at risk
FETZIMA® (levomilnacipran extended release \[ER\]) taken orally during flexible dose titration up to 40, 80 or 120 mg once daily in 8-week run-in period followed by fixed dose of 40, 80 or 120 mg once daily in 12-week stabilization period.
Double-Blind Placebo
n=159 participants at risk
Dose-matched placebo taken orally once daily for 26 weeks during double-blind treatment period.
Double-Blind FETZIMA®
n=165 participants at risk
FETZIMA® (levomilnacipran ER) taken orally at fixed dose of 40, 80 or 120 mg once daily for 26 weeks during double-blind treatment period.
Gastrointestinal disorders
Nausea
27.0%
174/644 • Up to 48 weeks
3.1%
5/159 • Up to 48 weeks
7.9%
13/165 • Up to 48 weeks
Gastrointestinal disorders
Constipation
10.7%
69/644 • Up to 48 weeks
1.9%
3/159 • Up to 48 weeks
1.8%
3/165 • Up to 48 weeks
Gastrointestinal disorders
Dry mouth
5.7%
37/644 • Up to 48 weeks
1.3%
2/159 • Up to 48 weeks
0.00%
0/165 • Up to 48 weeks
Nervous system disorders
Headache
16.0%
103/644 • Up to 48 weeks
7.5%
12/159 • Up to 48 weeks
10.3%
17/165 • Up to 48 weeks
Nervous system disorders
Dizziness
7.8%
50/644 • Up to 48 weeks
2.5%
4/159 • Up to 48 weeks
0.61%
1/165 • Up to 48 weeks
Investigations
Heart rate increased
11.0%
71/644 • Up to 48 weeks
2.5%
4/159 • Up to 48 weeks
2.4%
4/165 • Up to 48 weeks
Investigations
Blood pressure increased
5.6%
36/644 • Up to 48 weeks
1.9%
3/159 • Up to 48 weeks
3.0%
5/165 • Up to 48 weeks
Skin and subcutaneous tissue disorders
Hyperhidrosis
8.9%
57/644 • Up to 48 weeks
1.3%
2/159 • Up to 48 weeks
0.61%
1/165 • Up to 48 weeks
Cardiac disorders
Tachycardia
7.8%
50/644 • Up to 48 weeks
1.9%
3/159 • Up to 48 weeks
3.6%
6/165 • Up to 48 weeks
Infections and infestations
Upper respiratory tract infection
7.1%
46/644 • Up to 48 weeks
6.3%
10/159 • Up to 48 weeks
9.7%
16/165 • Up to 48 weeks
Psychiatric disorders
Insomnia
5.3%
34/644 • Up to 48 weeks
1.3%
2/159 • Up to 48 weeks
3.0%
5/165 • Up to 48 weeks
Infections and infestations
Nasopharyngitis
3.9%
25/644 • Up to 48 weeks
4.4%
7/159 • Up to 48 weeks
6.7%
11/165 • Up to 48 weeks

Additional Information

Therapeutic Area Head

Allergan

Phone: 714-246-4500

Results disclosure agreements

  • Principal investigator is a sponsor employee A disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 90 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.
  • Publication restrictions are in place

Restriction type: OTHER